This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7-30. 10.3322/caac.21387SiegelRLMillerKDJemalA.Cancer statistics, 2017CA Cancer J Clin20176773010.3322/caac.21387Open DOISearch in Google Scholar
Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, du Bois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol 2016; 142: 597-607. 10.1016/j.ygyno.2016.06.013AtasevenBChivaLMHarterPGonzalez-MartinAdu Bois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisitedGynecol Oncol201614259760710.1016/j.ygyno.2016.06.013Open DOISearch in Google Scholar
Kumar L, Pramanik R, Kumar S, Bhatla N, Malik S. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging. Best Pract Res Clin Obstet Gynaecol 2015; 29: 790-801. 10.1016/j.bpobgyn.2015.02.008KumarLPramanikRKumarSBhatlaNMalikS.Neoadjuvant chemotherapy in gynaecological cancers - Implications for stagingBest Pract Res Clin Obstet Gynaecol20152979080110.1016/j.bpobgyn.2015.02.008Open DOISearch in Google Scholar
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe ďInvestigateurs Nationaux Pour les Etudes des Cancers de ľOvaire (GINECO). Cancer 2009 15; 115: 1234-44. 10.1002/cncr.24149du BoisAReussAPujade-LauraineEHarterPRay-CoquardIPfistererJ.Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe ďInvestigateurs Nationaux Pour les Etudes des Cancers de ľOvaire (GINECO)Cancer 2009 1511512344410.1002/cncr.24149Open DOISearch in Google Scholar
Kessous R, Laskov I, Abitbol J, Bitharas J, Yasmeen A, Salvador S, et al. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 2017; 144: 474-9. 10.1016/j.ygyno.2016.12.017KessousRLaskovIAbitbolJBitharasJYasmeenASalvadorSClinical outcome of neoadjuvant chemotherapy for advanced ovarian cancerGynecol Oncol2017144474910.1016/j.ygyno.2016.12.017Open DOISearch in Google Scholar
Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, et al. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecol Oncol 2015; 139: 394-400. 10.1016/j.ygyno.2015.08.026LiuZBeachJAAgadjanianHJiaDAspuriaPJKarlanBYSuboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activationGynecol Oncol201513939440010.1016/j.ygyno.2015.08.026Open DOISearch in Google Scholar
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, Lu KH, Sood AK, Coleman RL, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol 2015; 137: 553-8. 10.1016/j.ygyno.2015.03.049Gómez-HidalgoNRMartinez-CannonBANickAMLuKHSoodAKColemanRLPredictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of careGynecol Oncol2015137553810.1016/j.ygyno.2015.03.049Open DOISearch in Google Scholar
Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol 2016; 143: 236-40. 10.1016/j.ygyno.2016.09.002MelamedAHinchcliffEMClemmerJTBregarAJUppalSBostockITrends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United StatesGynecol Oncol20161432364010.1016/j.ygyno.2016.09.002Open DOISearch in Google Scholar
May T, Comeau R, Sun P, Kotsopoulos J, Narod SA, Rosen B, et al. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. Int J Gynecol Cancer 2017; 27: 668-74. 10.1097/IGC.0000000000000946MayTComeauRSunPKotsopoulosJNarodSARosenBA Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant ChemotherapyInt J Gynecol Cancer2017276687410.1097/IGC.0000000000000946Open DOISearch in Google Scholar
Mueller JJ, Zhou QC, Iasonos A, O’Cearbhaill RE, Alvi FA, El Haraki A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol 2016; 140: 436-42. 10.1016/j.ygyno.2016.01.008MuellerJJZhouQCIasonosAO’CearbhaillREAlviFAEl HarakiANeoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer centerGynecol Oncol20161404364210.1016/j.ygyno.2016.01.008Open DOISearch in Google Scholar
Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol 2014; 134: 462-7. 10.1016/j.ygyno.2014.07.004RosenBLaframboiseSFergusonSDodgeJBernardiniMMurphyJThe impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancerGynecol Oncol2014134462710.1016/j.ygyno.2014.07.004Open DOISearch in Google Scholar
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-57. 10.1016/S0140-6736(14)62223-6KehoeSHookJNankivellMJaysonGCKitchenerHLopesTPrimary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trialLancet20153862495710.1016/S0140-6736(14)62223-6Open DOISearch in Google Scholar
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53. 10.1056/NEJMoa0908806VergoteITropéCGAmantFKristensenGBEhlenTJohnsonNEuropean Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancerN Engl J Med20103639435310.1056/NEJMoa0908806Open DOISearch in Google Scholar
Mahner S, Trillsch F, Chi D, Harter P, Pfisterer J, Hilpert F, et al. Neoadjuvant chemotherapy in ovarian cancer revisited. Ann Oncol 2016; 27 (Suppl 1): i30-2. 10.1093/annonc/mdw092MahnerSTrillschFChiDHarterPPfistererJHilpertFNeoadjuvant chemotherapy in ovarian cancer revisitedAnn Oncol201627130210.1093/annonc/mdw092Open DOISearch in Google Scholar
Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological Oncology. Int J Gynecol Cancer 2012; 22: 407-16. 10.1097/IGC.0b013e31823ea1d8CornelisSVan CalsterBAmantFLeunenKvan der ZeeAGVergoteI.Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European Society of Gynecological OncologyInt J Gynecol Cancer2012224071610.1097/IGC.0b013e31823ea1d8Open DOISearch in Google Scholar
Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecol Oncol 2010; 119: 18-21. 10.1016/j.ygyno.2010.06.021DewdneySBRimelBJReinhartAJKizerNTBrooksRAMassadLSThe role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic OncologistsGynecol Oncol2010119182110.1016/j.ygyno.2010.06.021Open DOISearch in Google Scholar
Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003; 88: 9-16. 10.1006/gyno.2002.6849ChanYMNgTYNganHYWongLC.Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal studyGynecol Oncol20038891610.1006/gyno.2002.6849Open DOISearch in Google Scholar
Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, et al. European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecol Oncol 2013; 131: 437-44. 10.1016/j.ygyno.2013.08.014GreimelEKristensenGBvan der BurgMECoronadoPRustinGdel RioASEuropean Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapyGynecol Oncol20131314374410.1016/j.ygyno.2013.08.014Open DOISearch in Google Scholar
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96. 10.1097/SLA.0b013e3181b13ca2ClavienPABarkunJde OliveiraMLVautheyJNDindoDSchulickRDThe Clavien-Dindo classification of surgical complications: five-year experienceAnn Surg20092501879610.1097/SLA.0b013e3181b13ca2Open DOISearch in Google Scholar
Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions. Ann Oncol 2017; 28: 711-7. 10.1093/annonc/mdx011KaramALedermannJAKimJWSehouliJLuKGourleyCFifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventionsAnn Oncol201728711710.1093/annonc/mdx011Open DOISearch in Google Scholar
Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 2013; 130: 493-8. 10.1016/j.ygyno.2013.05.040ChangSJHodeibMChangJBristowRE.Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysisGynecol Oncol2013130493810.1016/j.ygyno.2013.05.040Open DOISearch in Google Scholar
Brand AH. Ovarian cancer debulking surgery: a survey of practice in Australia and New Zealand. Int J Gynecol Cancer 2011; 21: 30-5. 10.1097/IGC.0b013e318205fb4fBrandAH.Ovarian cancer debulking surgery: a survey of practice in Australia and New ZealandInt J Gynecol Cancer20112130510.1097/IGC.0b013e318205fb4fOpen DOISearch in Google Scholar
Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. Gynecol Oncol 2016; 142: 211-6. 10.1016/j.ygyno.2016.05.025Dahm-KählerPPalmqvistCStafCHolmbergEJohannessonL.Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort studyGynecol Oncol2016142211610.1016/j.ygyno.2016.05.025Open DOISearch in Google Scholar
Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, et al. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database. JAMA Oncol 2017; 3: 76-82. 10.1001/jamaoncol.2016.4411Rauh-HainJAMelamedAWrightAGockleyAClemmerJTSchorgeJOOverall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer DatabaseJAMA Oncol20173768210.1001/jamaoncol.2016.4411Open DOISearch in Google Scholar
Petrillo M, Ferrandina G, Fagotti A, Vizzielli G, Margariti PA, Pedone AL, et al. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 2013; 20: 3955-60. 10.1245/s10434-013-3091-6PetrilloMFerrandinaGFagottiAVizzielliGMargaritiPAPedoneALTiming and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapyAnn Surg Oncol20132039556010.1245/s10434-013-3091-6Open DOISearch in Google Scholar
da Costa AA, Valadares CV, Baiocchi G, Mantoan H, Saito A, Sanches S, et al. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. Ann Surg Oncol 2015; 22 (Suppl 3): S971-8. 10.1245/s10434-015-4623-zda CostaAAValadaresCVBaiocchiGMantoanHSaitoASanchesSNeoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian CancerAnn Surg Oncol2015223S971810.1245/s10434-015-4623-zOpen DOISearch in Google Scholar
Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011; 12: 1169-74. 10.1016/S1470-2045(11)70123-1CookeSLBrentonJD.Evolution of platinum resistance in high-grade serous ovarian cancerLancet Oncol20111211697410.1016/S1470-2045(11)70123-1Open DOISearch in Google Scholar
Bian C, Yao K, Li L, Yi T, Zhao X. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer. Arch Gynecol Obstet 2016; 293: 63-8. 10.1007/s00404-015-3813-zBianCYaoKLiLYiTZhaoX.Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancerArch Gynecol Obstet201629363810.1007/s00404-015-3813-zOpen DOISearch in Google Scholar
Lim MC, Yoo HJ, Song YJ, Seo SS, Kang S, Kim SH, et al. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. J Gynecol Oncol 2017; 28: e48. 10.3802/jgo.2017.28.e48LimMCYooHJSongYJSeoSSKangSKimSHSurvival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancerJ Gynecol Oncol201728e4810.3802/jgo.2017.28.e48Open DOISearch in Google Scholar
Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015; 126: 491-7. 10.1097/AOG.0000000000000981CressRDChenYSMorrisCRPetersenMLeiserowitzGS.Characteristics of long-term survivors of epithelial ovarian cancerObstet Gynecol2015126491710.1097/AOG.0000000000000981Open DOISearch in Google Scholar
Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep 2014; 16: 389. 10.1007/s11912-014-0389-xBrownJFrumovitzM.Mucinous tumors of the ovary: current thoughts on diagnosis and managementCurr Oncol Rep20141638910.1007/s11912-014-0389-xOpen DOISearch in Google Scholar
Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, et al. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol 2017; 144: 57-60. 10.1016/j.ygyno.2016.11.001MarchettiCKristeleitRMcCormackMMouldTOlaitanAWidschwendterMOutcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective reviewGynecol Oncol2017144576010.1016/j.ygyno.2016.11.001Open DOISearch in Google Scholar
Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection. Gynecol Oncol 2017; 144: 266-73. 10.1016/j.ygyno.2016.11.021GillSEMcGreeMEWeaverALClibyWALangstraatCL.Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resectionGynecol Oncol20171442667310.1016/j.ygyno.2016.11.021Open DOISearch in Google Scholar
